Thomas Keuer
Chief Executive Officer bei ARCA BIOPHARMA, INC.
Vermögen: 71 685 $ am 31.03.2024
Profil
Thomas A.
Keuer is currently the President & Chief Executive Officer at ARCA biopharma, Inc. He previously held the position of Vice President-Engineering at Baxter Healthcare Corp.
and Baxter International, Inc. He also served as Vice President-Operations at Somatogen, Inc. and as Senior Vice President-Operations at Insmed, Inc. Additionally, he was the Executive Vice President-Pharmaceutical Operations at ARCA biopharma, Inc. Mr. Keuer graduated from Rice University with a graduate degree and from The University of Texas at Austin with an undergraduate degree.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ARCA BIOPHARMA, INC.
0,28% | 22.01.2024 | 40 730 ( 0,28% ) | 71 685 $ | 31.03.2024 |
Aktive Positionen von Thomas Keuer
| Unternehmen | Position | Beginn |
|---|---|---|
| ARCA BIOPHARMA, INC. | Chief Executive Officer | 03.04.2024 |
Ehemalige bekannte Positionen von Thomas Keuer
| Unternehmen | Position | Ende |
|---|---|---|
ARCA biopharma, Inc. /Old/
 ARCA biopharma, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ARCA biopharma, Inc. develops genetic therapies for heart failure and cardiovascular diseases. It offers Gencaro product, is an investigational pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. The company was founded by Michael R. Bristow and is headquartered in Denver, CO. | Chief Operating Officer | 29.01.2009 |
| INSMED INCORPORATED | Chief Operating Officer | 01.11.2006 |
| BAXTER INTERNATIONAL INC. | Chief Tech/Sci/R&D Officer | 01.01.2004 |
Baxter Healthcare Corp.
 Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Corporate Officer/Principal | 01.01.2004 |
Somatogen, Inc.
 Somatogen, Inc. BiotechnologyHealth Technology Somatogen, Inc. develops specialty oxygen therapeutics. It is engaged in the research, clinical development and commercialization of genetically engineered recombinant human hemoglobin-based products. The company is located in Boulder, CO. | Chief Operating Officer | - |
Ausbildung von Thomas Keuer
| Rice University | Graduate Degree |
| The University of Texas at Austin | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| BAXTER INTERNATIONAL INC. | Health Technology |
| INSMED INCORPORATED | Health Technology |
| ARCA BIOPHARMA, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Health Technology |
Somatogen, Inc.
Somatogen, Inc. BiotechnologyHealth Technology Somatogen, Inc. develops specialty oxygen therapeutics. It is engaged in the research, clinical development and commercialization of genetically engineered recombinant human hemoglobin-based products. The company is located in Boulder, CO. | Health Technology |
ARCA biopharma, Inc. /Old/
ARCA biopharma, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ARCA biopharma, Inc. develops genetic therapies for heart failure and cardiovascular diseases. It offers Gencaro product, is an investigational pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. The company was founded by Michael R. Bristow and is headquartered in Denver, CO. | Health Technology |
